CA2289600A1 - Techniques et compositions destinees au traitement d'une insuffisance cardiaque et du remodelage ventriculaire par apport in vivo de transgenes angiogeniques - Google Patents
Techniques et compositions destinees au traitement d'une insuffisance cardiaque et du remodelage ventriculaire par apport in vivo de transgenes angiogeniques Download PDFInfo
- Publication number
- CA2289600A1 CA2289600A1 CA002289600A CA2289600A CA2289600A1 CA 2289600 A1 CA2289600 A1 CA 2289600A1 CA 002289600 A CA002289600 A CA 002289600A CA 2289600 A CA2289600 A CA 2289600A CA 2289600 A1 CA2289600 A1 CA 2289600A1
- Authority
- CA
- Canada
- Prior art keywords
- angiogenic protein
- fgf
- vegf
- vector
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 61
- 206010019280 Heart failures Diseases 0.000 title claims abstract 6
- 208000033774 Ventricular Remodeling Diseases 0.000 title claims abstract 4
- 238000001727 in vivo Methods 0.000 title abstract 2
- 108700019146 Transgenes Proteins 0.000 title 1
- 230000002491 angiogenic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000008076 Angiogenic Proteins Human genes 0.000 claims abstract 46
- 108010074415 Angiogenic Proteins Proteins 0.000 claims abstract 46
- 239000013598 vector Substances 0.000 claims abstract 19
- 238000002347 injection Methods 0.000 claims abstract 9
- 239000007924 injection Substances 0.000 claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract 5
- 210000004204 blood vessel Anatomy 0.000 claims abstract 5
- 210000004165 myocardium Anatomy 0.000 claims abstract 5
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims abstract 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims abstract 2
- 208000029078 coronary artery disease Diseases 0.000 claims abstract 2
- 230000002939 deleterious effect Effects 0.000 claims abstract 2
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 6
- 210000004351 coronary vessel Anatomy 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 4
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims 4
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims 4
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims 4
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 102000013275 Somatomedins Human genes 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims 4
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims 2
- 101000629029 Homo sapiens Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims 2
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 claims 2
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims 2
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 108010051583 Ventricular Myosins Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 210000001349 mammary artery Anatomy 0.000 claims 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims 2
- 210000003752 saphenous vein Anatomy 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des procédés destinés au traitement de patients souffrant d'insuffisance cardiaque globale (y compris de myocardiopathie dilatée et d'insuffisance cardiaque globale associée à une coronaropathie grave) ainsi qu'à la prévention ou à la limitation du remodelage ventriculaire nuisible à la santé après un infarctus du myocarde. Les procédés préférés de la présente invention comprennent l'apport in vivo au myocarde de gènes codant des protéines angiogéniques ou peptides, par injection directe d'un vecteur contenant le gène dans un vaisseau sanguin irriguant le coeur.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/852,779 | 1997-05-06 | ||
| US85277997A | 1997-05-07 | 1997-05-07 | |
| PCT/US1998/008848 WO1998050079A2 (fr) | 1997-05-06 | 1998-04-30 | Techniques et compositions destinees au traitement d'une insuffisance cardiaque et du remodelage ventriculaire par apport in vivo de transgenes angiogeniques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2289600A1 true CA2289600A1 (fr) | 1998-11-12 |
| CA2289600C CA2289600C (fr) | 2010-06-29 |
Family
ID=25314196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2289600A Expired - Fee Related CA2289600C (fr) | 1997-05-06 | 1998-04-30 | Techniques et compositions destinees au traitement d'une insuffisance cardiaque et du remodelage ventriculaire par apport in vivo de transgenes angiogeniques |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0980428A2 (fr) |
| JP (1) | JP2002515065A (fr) |
| KR (2) | KR20010012313A (fr) |
| CN (1) | CN1267331A (fr) |
| AU (1) | AU7173598A (fr) |
| CA (1) | CA2289600C (fr) |
| EA (1) | EA005157B1 (fr) |
| WO (1) | WO1998050079A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2329934A1 (fr) * | 1998-05-30 | 1999-12-09 | Collateral Therapeutics, Inc. | Procedes de modification du phenotype de la cellule cardiaque |
| DE19915485A1 (de) * | 1999-04-07 | 2000-10-19 | Hugo A Katus | Therapie der Herzinsuffizienz |
| KR20020049031A (ko) * | 1999-11-05 | 2002-06-24 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물 |
| EP1294407A2 (fr) * | 2000-06-30 | 2003-03-26 | Collateral Therapeutics | Compositions de therapie genique renfermant deux genes recombines, et methodes d'utilisation correspondantes |
| KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
| JP2010523264A (ja) | 2007-04-11 | 2010-07-15 | ヘンリー フォード ヘルス システム | 心臓の静脈系を用いた心臓の修復、リサイジング、およびリシェイピング |
| CA2715765A1 (fr) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions pour un captage ameliore de vecteurs viraux dans le myocarde |
| ES2556711T3 (es) | 2008-04-09 | 2016-01-19 | Viromed Co., Ltd. | Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico |
| CA2723276A1 (fr) | 2008-05-02 | 2009-11-05 | University Of Western Ontario | Fgf-9 et son utilisation se rapportant aux vaisseaux sanguins |
| CN104220098B (zh) * | 2012-02-14 | 2018-04-10 | 加利福尼亚大学董事会 | 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达 |
| ES2773305T3 (es) | 2013-10-22 | 2020-07-10 | Helixmith Co Ltd | Composición para la prevención o tratamiento de la esclerosis lateral amiotrófica que utiliza dos o más isoformas del factor de crecimiento de hepatocitos |
| JP7212230B2 (ja) | 2018-07-19 | 2023-01-25 | ヘリックスミス カンパニー， リミテッド | ネイキッドｄｎａ遺伝子療法のための凍結乾燥した薬剤学的組成物 |
| CN109517807A (zh) * | 2018-11-20 | 2019-03-26 | 暨南大学 | 一种心脏血管靶向的噬菌体载体及其用途 |
| US20220143142A1 (en) * | 2019-03-17 | 2022-05-12 | Baylor College Of Medicine | Direct reprogramming of cardiac fibroblasts into cardiomyocytes using an endothelial cell transdifferentiation strategy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2188575A1 (fr) * | 1995-02-28 | 1996-09-06 | H. Kirk Hammond | Therapie angiogenique par transfert de genes |
-
1998
- 1998-04-30 CA CA2289600A patent/CA2289600C/fr not_active Expired - Fee Related
- 1998-04-30 KR KR1019997010265A patent/KR20010012313A/ko not_active Application Discontinuation
- 1998-04-30 EP EP98918904A patent/EP0980428A2/fr not_active Ceased
- 1998-04-30 WO PCT/US1998/008848 patent/WO1998050079A2/fr active Application Filing
- 1998-04-30 JP JP54824398A patent/JP2002515065A/ja active Pending
- 1998-04-30 CN CN98806526A patent/CN1267331A/zh active Pending
- 1998-04-30 EA EA199901002A patent/EA005157B1/ru not_active IP Right Cessation
- 1998-04-30 AU AU71735/98A patent/AU7173598A/en not_active Abandoned
- 1998-04-30 KR KR1020067026818A patent/KR20070005030A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998050079A3 (fr) | 1999-02-04 |
| KR20010012313A (ko) | 2001-02-15 |
| CA2289600C (fr) | 2010-06-29 |
| CN1267331A (zh) | 2000-09-20 |
| EP0980428A2 (fr) | 2000-02-23 |
| AU7173598A (en) | 1998-11-27 |
| JP2002515065A (ja) | 2002-05-21 |
| KR20070005030A (ko) | 2007-01-09 |
| EA199901002A1 (ru) | 2000-08-28 |
| WO1998050079A2 (fr) | 1998-11-12 |
| EA005157B1 (ru) | 2004-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2289600A1 (fr) | Techniques et compositions destinees au traitement d'une insuffisance cardiaque et du remodelage ventriculaire par apport in vivo de transgenes angiogeniques | |
| Rissanen et al. | Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb–on the way to the clinic | |
| Cao et al. | Update on therapeutic neovascularization | |
| Melillo et al. | Gene therapy for collateral vessel development | |
| US20030053989A1 (en) | Method of modulating neovascularization | |
| Hamawy et al. | Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization | |
| JP2003513942A5 (fr) | ||
| Kusumanto et al. | Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review | |
| Maulik et al. | Growth factor/s and cell therapy in myocardial regeneration | |
| Fukuda et al. | Angiogenic strategy for human ischemic heart disease: brief overview | |
| JP2002502885A5 (fr) | ||
| EP1695719A1 (fr) | Combinaision d'une acide nucléaire et d'un agent vasoactif pour l'amélioration de transfert de gènes | |
| US7709450B2 (en) | Stimulation of vascularization with VEGF-B-186 | |
| AU1477101A (en) | Method of inducing angiogenesis | |
| Stegmann | New approaches to coronary heart disease: induction of neovascularisation by growth factors | |
| Huemer et al. | Adenovirus-mediated transforming growth factor-β ameliorates ischemic necrosis of epigastric skin flaps in a rat model1, 2 | |
| Sim et al. | Therapeutic angiogenesis for coronary artery disease | |
| Idris et al. | Therapeutic angiogenesis for treatment of peripheral vascular disease | |
| EP1294407A2 (fr) | Compositions de therapie genique renfermant deux genes recombines, et methodes d'utilisation correspondantes | |
| Schalch et al. | Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state | |
| Bashir et al. | Angiogenic gene therapy: pre-clinical studies and phase I clinical data | |
| US7727971B2 (en) | Use of placental growth factor for treating ischemic muscle disease | |
| Stegmann et al. | Combined Local Angiogenesis and Surgical Revascularization for | |
| Symes | Gene therapy for ischemic heart disease: therapeutic potential | |
| AU3202999A (en) | Use of scatter factor to enhance angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180430 |